What Cayston treats: Main Uses and Benefits

Cayston is commonly used for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in patients with Cystic Fibrosis (CF). The therapy is applicable for conditions involving episodic or fluctuating manifestations. It is generally used to help with suppressing the bacterial infection and supports functional stability in CF patients aged six years and older.

The medication helps address symptom clusters that may become intense or disruptive, specifically chronic coughing and increased sputum production. Applied during phases of increased distress or discomfort, this targeted approach supports patients during difficult episodes by easing distress and contributes to easing the overall symptom load. It is relevant for managing symptoms that interfere with daily comfort. Used in situations involving recurrent or episodic manifestations, this strategy may assist with managing the risk of pulmonary exacerbations.

---

Quick Fact: Symptomatic Relief Context

Cayston is considered relevant for easing symptoms that interfere with daily comfort in patients with Cystic Fibrosis, helping them cope more steadily with chronic manifestations like mucus production and persistent cough.

Cayston (aztreonam for inhalation) eligibility is strictly defined by regulatory authorities and centers on the patient's underlying condition and specific clinical status.

Who Is Eligible?

Use is authorized for patients diagnosed with Cystic Fibrosis (CF) who have a chronic pulmonary infection caused by Pseudomonas aeruginosa in the lungs. Use is generally approved for adults and children aged 6 years and older (EU/UK) or 7 years and older (US). Safety and effectiveness are not established in children below these minimum age thresholds.

---

Who Must Not Use Cayston (Contraindications)?

The medicine is contraindicated in any patient with a known allergy or hypersensitivity to aztreonam or to any of the excipients used in the product's formulation.

---

Populations with Restrictions or Conditional Use

Use is not established in patients co-infected with Burkholderia cepacia or those whose lung function falls outside the moderate range studied (FEV1 <25% or >75% predicted). Caution is advised for patients with a history of beta-lactam allergy and those with significant renal impairment. Regarding pregnancy, use should not be employed unless the clinical condition requires treatment, as aztreonam is known to be excreted in human milk.

Cayston Interactions with other medicines and products

The official interaction profile for Cayston (aztreonam lysine for inhalation) is based on specific administration rules, as formal clinical studies of systemic drug-drug interactions have not been conducted for this inhaled formulation. The resultant profile focuses on mandatory sequencing rather than systemic metabolic changes.

---

Administration Timing and Sequencing Rules

The medication must be administered last in the sequence of all prescribed inhaled cystic fibrosis therapies. Individual doses must be spaced at least four hours apart.

• Bronchodilators must be taken prior to the Cayston dose. Short-acting bronchodilators require a separation of 15 minutes to 4 hours before the dose, while long-acting bronchodilators require a separation of 30 minutes to 12 hours.
• Mucolytics must be administered after a bronchodilator but immediately before Cayston to maintain the proper inhalation sequence.

---

Physical and Other Constraints

• Physical Restriction: The co-mixing of Cayston with any other drug in the nebulizer handset is strictly prohibited.
• Systemic Interaction Context: No evidence of drug interactions was identified in clinical trials when Cayston was used concurrently with medicines such as dornase alfa, oral steroids, inhaled steroids, azithromycin, or tobramycin.
• Population Note: Caution is noted for administration in patients with renal impairment (serum creatinine exceeding twice the upper limit of normal). This consideration is based on the known renal excretion of aztreonam, though low systemic exposure via inhalation prevents the need for a formal dose adjustment.

Targeting the Bacterial Cell Wall for Destruction

The drug's active component, aztreonam, is a beta-lactam antimicrobial that selectively targets the bacterial enzyme Penicillin-Binding Protein 3 (PBP-3). Aztreonam functions as a highly specific inhibitor by binding to PBP-3, which is critical for the transpeptidation step in peptidoglycan synthesis. This binding prevents the final cross-linking necessary for constructing the structural integrity of the bacterial cell wall.

Cascade Leading to Airway Modulation

The inability to form a stable cell wall leads to the breakdown of the bacterial structure, resulting in rapid cell lysis and death. This bactericidal action reduces the bacterial population density locally within the airways. This decrease in viable organisms modifies the concentration of inflammatory mediators, which are associated with the presence of bacteria. This process produces a physiological consequence that impacts airway-related pressure dynamics.

How to Use Cayston — Official Administration Guidelines

Cayston is strictly administered via the inhalation route using a specific nebulisation system and is not approved for intravenous or intramuscular use. The official regimen involves a fixed dose of 75 mg of aztreonam per administration, which is prepared by reconstituting the lyophilized powder with 1 mL of the supplied diluent just prior to use. The medicine must be administered 3 times a day (TID), with a mandatory minimum of 4 hours separating each dose.

Treatment Cycle and Age: Use is structured around a non-continuous cyclic pattern that consists of 28 consecutive days on therapy, immediately followed by 28 consecutive days off therapy, with the cycle repeating as directed. The 75 mg TID dosage is standardized for adults and for pediatric patients, generally starting between 6 and 7 years of age.

Procedural Requirements: The medicine must be administered using the Altera® Nebulizer System or an equivalent approved device, as no other nebuliser is authorized for use. A bronchodilator must be administered before each dose of Cayston to fulfill the procedural requirement for use. For individuals taking multiple inhaled therapies, the official sequence dictates that Cayston must be administered last, following any bronchodilators and mucolytics. If a dose is missed, it may be taken as soon as possible, provided the 4-hour interval before the next dose is strictly maintained. The final reconstituted solution must be clear and never mixed with other drugs in the nebulizer handset.

Research evidence / Overview of studies for Cayston

Evidence for Use in Chronic P. aeruginosa Infection in Cystic Fibrosis

The core evidence base for this medicine was studied for the indication of chronic lung infection due to Pseudomonas aeruginosa in people with Cystic Fibrosis (CF). The primary research consisted of short-term, randomized, double-blind, placebo-controlled trials that research examined over a single 28-day course of treatment. These trials typically included adults and children applied in studies examining patient-reported experiences in individuals with moderate lung function.

In these studies, researchers monitored specific endpoints related to symptoms and lung function. The central functional outcome was evaluated in the form of changes in Forced Expiratory Volume in 1 second ( FEV1), a measure of lung function. Studies also tracked microbiological outcomes by measuring changes in the density of P. aeruginosa bacteria in the sputum, and described measurements related to the time until patients required additional antibiotics, which is a proxy outcome relevant in trials assessing short-term or episodic symptom patterns associated with pulmonary exacerbation.

Long-Term Research and Repeated Treatment Cycles

The evidence supporting the use of the drug in intermittent, repeating courses comes largely from open-label extension (OLE) studies and long-term observational follow-up. These studies were observed in participants who were followed through multiple cycles (28 days on treatment and 28 days off) for up to 18 months. Unlike the short-term pivotal trials, these OLE studies did not include a placebo comparator for the full duration.

What Remains Uncertain: Research Gaps and Limitations

Scientific reviews consistently note specific areas where certainty remains low. One key limitation is the absence of long-term, blinded controlled data; the observation of effects beyond a few months is based mostly on open-label follow-up, where the study blinding was absent. Furthermore, evidence is limited regarding patients at the extremes of disease severity. Research monitored changes in the susceptibility of P. aeruginosa bacteria to aztreonam and other antibiotics over time; while the clinical significance of these resistance changes is not fully established, this remains a subject of ongoing concern in the broader evidence landscape.

Key Studies & References

1. Gilead Announces Preliminary Results From Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis (Reporting on AIR-CF2 time to exacerbation outcome)

Common questions about Cayston (FAQ)

---

Q: How quickly can a patient expect to feel a difference after starting Cayston?

Clinical trials measured changes in lung function and patient-reported symptoms after a full 28-day course of treatment. Official documents indicate that significant improvement in patient-reported respiratory symptoms and FEV1 (a measure of lung function) was observed following this 28-day period.

---

Q: What is the difference between Cayston and other inhaled antibiotics like Tobramycin (TOBI)?

Cayston’s active ingredient, aztreonam, belongs to a specific class of antibiotics known as monobactams. This drug class has a distinct chemical structure. Official product information notes that this difference results in a low risk of cross-reactivity with other beta-lactam antibiotics, such as penicillins and cephalosporins.

---

Q: Does Cayston cause an initial increase in coughing or wheezing when first starting treatment?

Trouble breathing, or bronchospasm, is a potential adverse reaction that can occur right after a dose is administered. For this reason, official safety information stipulates that a bronchodilator be administered before each dose. This practice is intended to help mitigate the potential for sudden trouble breathing.

---

Q: Is a fever or flu-like feeling a common side effect of Cayston, and how long does it usually last?

Fever (pyrexia) is listed as a very common side effect in regulatory documents, meaning it affects more than 1 in 10 people. The official drug label confirms this possible reaction but does not specify the typical duration of the fever or describe the feeling as 'flu-like'.

---

Q: Can Cayston be used if a patient has known allergies to other beta-lactam antibiotics (like penicillin)?

Official information advises caution for patients who have a history of allergy to other beta-lactam antibiotics. Aztreonam is a monobactam, and clinical data shows it has a low risk of causing cross-reactivity with these other drug classes.

---

Q: Is it safe to use Cayston during pregnancy or while breastfeeding?

Official regulatory documents advise that use during pregnancy should occur only if the clinical condition requires it. Aztreonam is known to be excreted in human milk, and official product information states that use may occur during breastfeeding.

---

Q: Can Cayston be used by patients who have a history of coughing up blood (hemoptysis)?

Administration in patients with active hemoptysis (coughing up blood) requires careful consideration. Official safety notes describe that administration in these situations is restricted to where the potential benefits are considered to outweigh the risks of inducing further hemorrhage.

---

Q: What were the major patient concerns and misconceptions about Cayston that researchers studied?

Clinical trials utilized the Cystic Fibrosis Questionnaire-Revised (CFQ-R) to measure patient-reported outcomes. Researchers focused on the drug's impact on respiratory symptoms, emotional well-being, and physical functioning, which represent the major areas of patient concern examined in the studies.

---

Q: What are the reported side effects for children aged 7 and older taking Cayston?

The recommended dosage regimen is the same for both adults and pediatric patients aged 7 years and older (or 6 years and older, depending on the regulatory region). The reported side effect profile described in the official label is considered applicable to this entire population.

---

Q: Is Cayston effective against other bacteria sometimes found in the lungs of CF patients?

Cayston is specifically indicated for chronic pulmonary infection due to Pseudomonas aeruginosa. However, official microbiology sections note that its active ingredient, aztreonam, has bactericidal activity against a wide range of aerobic Gram-negative bacteria.

---

Q: Does the efficacy of Cayston change for adults versus pediatric patients?

The recommended dose is standardized and is not adjusted based on a patient’s age or weight for those aged 7 and older. Efficacy measures were evaluated across the overall clinical trial population, and clinical benefits were observed in this combined group of adults and children.

---

Q: Is there data on long-term safety of using repeated cycles of Cayston over many years?

Research supporting the use of repeated courses of therapy comes from open-label extension studies. These studies followed participants for periods of up to 18 months using the 28-day on/off cycle. Data beyond this time frame for continuous, long-term use is not provided in the official labels.

---

Q: Why must the doses of Cayston be taken at least four hours apart?

Official product information notes that the doses must be spaced apart by a minimum of four hours. This requirement is based on the drug's pharmacokinetics and is designed to prevent systemic accumulation of the medicine in the body.

---

Q: Why is a rash considered a serious side effect that requires stopping Cayston immediately?

A rash or skin changes can be a sign of a severe allergic (hypersensitivity) reaction, which is classified as a serious adverse event. Regulatory warnings state that if signs of a severe allergic reaction occur, treatment cessation and immediate medical attention are necessary.

---

Q: Does Cayston come as a generic option, or is it only available as the brand name?

According to regulatory status information, the medicine is currently available only as the brand-name drug, Cayston. There is no FDA-approved generic alternative available for this specific inhaled formulation.

---

Q: What does the 28-day off period of the treatment cycle accomplish?

The purpose of the cyclic schedule (28 days on, 28 days off) is described in official documents. This treatment pattern is used to help reduce the potential for the development of drug-resistant bacteria and to maintain the long-term effectiveness of the antibiotic therapy.

---

Q: Does Cayston treatment improve overall quality of life based on clinical trial results?

Yes, official clinical trial results show that the treatment improved scores on several patient-reported quality of life measures. These included significant positive changes in scales related to respiratory symptoms, physical functioning, and emotional well-being.

---

Q: What are the chances of experiencing a severe allergic reaction to Cayston?

Severe allergic reactions are listed in official documents as a serious side effect that requires medical attention. The drug label emphasizes the severity of this risk but does not provide a specific chance or incidence rate (a percentage) for this event.

---

How to Store and Dispose of Cayston

The unopened Cayston vials (powder) and the diluent ampules must be stored in the original carton and kept in a refrigerator at a temperature between 2 C and 8 C (36 F and 46 F). The product must also be protected from light. For temporary storage, such as during travel, the unopened medicine may be kept at room temperature (up to 25 C or 77 F) for a maximum of 28 days.

After reconstitution with the diluent, the solution must be used immediately. If not administered right away, the mixed solution must be stored in the refrigerator and used within 8 hours. All medicine must be kept out of the reach of children.

Disposal instructions require that the empty vial and diluent ampule are discarded properly after use. Any unused or expired medicine must be disposed of in accordance with local requirements for pharmaceutical waste.